A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine

David J. Eyerman, Bryan Yamamoto

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Methamphetamine (METH) produces long-term decreases in markers of dopamine (DA) terminals in animals and humans. A decrease in the function of the vesicular monoamine transporter 2 (VMAT2) has been associated with damage to striatal DA terminals caused by METH; however, a possible mechanism for this decrease in VMAT2 function has not been defined. The current study showed that METH caused a rapid decrease to 68% of controls in VMAT2 protein immunoreactivity of the vesicular fraction from striatal synaptosomes within 1 h after a repeated high-dose administration regimen of METH. This decrease was associated with a 75% increase in nitrosylation of VMAT2 protein in the synaptosomal fraction as measured by nitrosocysteine immunoreactivity of VMAT2 protein. The rapid decreases in VMAT2 persisted when evaluated 7 days later and were illustrated by decreases in VMAT2 immunoreactivity and DA content of the vesicular fraction to 34% and 51% of control values, respectively. The decreases were blocked or attenuated by prior injections of the neuronal nitric oxide synthase inhibitor, S-methyl-l-thiocitrulline. These studies demonstrate that METH causes a rapid neuronal nitric oxide synthase-dependent oxidation of VMAT2 and long-term decreases in VMAT2 protein and function. The results also suggest that surviving DA terminals after METH exposure may have a compromised capacity to buffer cytosolic DA concentrations and DA-derived oxidative stress.

Original languageEnglish (US)
Pages (from-to)1219-1227
Number of pages9
JournalJournal of Neurochemistry
Volume103
Issue number3
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Vesicular Monoamine Transport Proteins
Methamphetamine
Oxidation
Dopamine
Nitric Oxide Synthase Type I
Corpus Striatum
Proteins
Oxidative stress
Buffers
Animals
Synaptosomes

Keywords

  • Dopamine
  • Methamphetamine
  • Nitric oxide
  • Vesicle
  • Vesicular monoamine transporter 2

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. / Eyerman, David J.; Yamamoto, Bryan.

In: Journal of Neurochemistry, Vol. 103, No. 3, 11.2007, p. 1219-1227.

Research output: Contribution to journalArticle

@article{710708d1213a459c8b28273627b4800b,
title = "A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine",
abstract = "Methamphetamine (METH) produces long-term decreases in markers of dopamine (DA) terminals in animals and humans. A decrease in the function of the vesicular monoamine transporter 2 (VMAT2) has been associated with damage to striatal DA terminals caused by METH; however, a possible mechanism for this decrease in VMAT2 function has not been defined. The current study showed that METH caused a rapid decrease to 68{\%} of controls in VMAT2 protein immunoreactivity of the vesicular fraction from striatal synaptosomes within 1 h after a repeated high-dose administration regimen of METH. This decrease was associated with a 75{\%} increase in nitrosylation of VMAT2 protein in the synaptosomal fraction as measured by nitrosocysteine immunoreactivity of VMAT2 protein. The rapid decreases in VMAT2 persisted when evaluated 7 days later and were illustrated by decreases in VMAT2 immunoreactivity and DA content of the vesicular fraction to 34{\%} and 51{\%} of control values, respectively. The decreases were blocked or attenuated by prior injections of the neuronal nitric oxide synthase inhibitor, S-methyl-l-thiocitrulline. These studies demonstrate that METH causes a rapid neuronal nitric oxide synthase-dependent oxidation of VMAT2 and long-term decreases in VMAT2 protein and function. The results also suggest that surviving DA terminals after METH exposure may have a compromised capacity to buffer cytosolic DA concentrations and DA-derived oxidative stress.",
keywords = "Dopamine, Methamphetamine, Nitric oxide, Vesicle, Vesicular monoamine transporter 2",
author = "Eyerman, {David J.} and Bryan Yamamoto",
year = "2007",
month = "11",
doi = "10.1111/j.1471-4159.2007.04837.x",
language = "English (US)",
volume = "103",
pages = "1219--1227",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine

AU - Eyerman, David J.

AU - Yamamoto, Bryan

PY - 2007/11

Y1 - 2007/11

N2 - Methamphetamine (METH) produces long-term decreases in markers of dopamine (DA) terminals in animals and humans. A decrease in the function of the vesicular monoamine transporter 2 (VMAT2) has been associated with damage to striatal DA terminals caused by METH; however, a possible mechanism for this decrease in VMAT2 function has not been defined. The current study showed that METH caused a rapid decrease to 68% of controls in VMAT2 protein immunoreactivity of the vesicular fraction from striatal synaptosomes within 1 h after a repeated high-dose administration regimen of METH. This decrease was associated with a 75% increase in nitrosylation of VMAT2 protein in the synaptosomal fraction as measured by nitrosocysteine immunoreactivity of VMAT2 protein. The rapid decreases in VMAT2 persisted when evaluated 7 days later and were illustrated by decreases in VMAT2 immunoreactivity and DA content of the vesicular fraction to 34% and 51% of control values, respectively. The decreases were blocked or attenuated by prior injections of the neuronal nitric oxide synthase inhibitor, S-methyl-l-thiocitrulline. These studies demonstrate that METH causes a rapid neuronal nitric oxide synthase-dependent oxidation of VMAT2 and long-term decreases in VMAT2 protein and function. The results also suggest that surviving DA terminals after METH exposure may have a compromised capacity to buffer cytosolic DA concentrations and DA-derived oxidative stress.

AB - Methamphetamine (METH) produces long-term decreases in markers of dopamine (DA) terminals in animals and humans. A decrease in the function of the vesicular monoamine transporter 2 (VMAT2) has been associated with damage to striatal DA terminals caused by METH; however, a possible mechanism for this decrease in VMAT2 function has not been defined. The current study showed that METH caused a rapid decrease to 68% of controls in VMAT2 protein immunoreactivity of the vesicular fraction from striatal synaptosomes within 1 h after a repeated high-dose administration regimen of METH. This decrease was associated with a 75% increase in nitrosylation of VMAT2 protein in the synaptosomal fraction as measured by nitrosocysteine immunoreactivity of VMAT2 protein. The rapid decreases in VMAT2 persisted when evaluated 7 days later and were illustrated by decreases in VMAT2 immunoreactivity and DA content of the vesicular fraction to 34% and 51% of control values, respectively. The decreases were blocked or attenuated by prior injections of the neuronal nitric oxide synthase inhibitor, S-methyl-l-thiocitrulline. These studies demonstrate that METH causes a rapid neuronal nitric oxide synthase-dependent oxidation of VMAT2 and long-term decreases in VMAT2 protein and function. The results also suggest that surviving DA terminals after METH exposure may have a compromised capacity to buffer cytosolic DA concentrations and DA-derived oxidative stress.

KW - Dopamine

KW - Methamphetamine

KW - Nitric oxide

KW - Vesicle

KW - Vesicular monoamine transporter 2

UR - http://www.scopus.com/inward/record.url?scp=35248900341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35248900341&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2007.04837.x

DO - 10.1111/j.1471-4159.2007.04837.x

M3 - Article

C2 - 17683483

AN - SCOPUS:35248900341

VL - 103

SP - 1219

EP - 1227

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 3

ER -